Aspirin use predicts prolonged survival in patients with oropharyngeal cancer: Nationwide Veterans Affairs database study.

MedStar author(s):
Citation: Head & Neck. 2020 Sep 22PMID: 32959950Institution: MedStar Health Research Institute | MedStar Washington Hospital CenterresidentDepartment: OtolaryngologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2020Local holdings: Available online from MWHC library: 1996 - presentISSN:
  • 1043-3074
Name of journal: Head & neckAbstract: BACKGROUND: Single-institution studies suggest that aspirin reduces the risk of death in head and neck cancer. The aim of this study was to investigate the effect of aspirin use on overall survival (OS) in veterans with oropharyngeal cancer (OPC).CONCLUSION: Aspirin use following OPC diagnosis was independently associated with improved 3-year OS among veterans nationwide. Copyright (c) 2020 Wiley Periodicals LLC.METHODS: A total of 23 083 veterans with OPC were identified between 2005 and 2018 from the Veterans Health Administration Corporate Data Warehouse. Records were queried for clinical-demographic data, aspirin prescriptions, and outcomes. Three-year OS was estimated. A Cox model was used to estimate hazard ratios (HR) for aspirin use.RESULTS: Among the 23 083 identified veterans, 17 206 veterans met inclusion criteria. 21.8% used aspirin. Three-year OS was prolonged for aspirin users (66%) compared to nonaspirin users (54%; P < .001). Adjusted HR for death for nonaspirin users was 1.75 (95% confidence interval (CI) [1.60-1.91]). The average treatment effect of aspirin on survival using inverse probability weighting was 10% (95% CI [0.08-0.11]).All authors: Clark CM, Fokar A, Maxwell JH, Newark ACFiscal year: FY2021Digital Object Identifier: ORCID: Date added to catalog: 2020-10-06
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 32959950 Available 32959950

Available online from MWHC library: 1996 - present

BACKGROUND: Single-institution studies suggest that aspirin reduces the risk of death in head and neck cancer. The aim of this study was to investigate the effect of aspirin use on overall survival (OS) in veterans with oropharyngeal cancer (OPC).

CONCLUSION: Aspirin use following OPC diagnosis was independently associated with improved 3-year OS among veterans nationwide. Copyright (c) 2020 Wiley Periodicals LLC.

METHODS: A total of 23 083 veterans with OPC were identified between 2005 and 2018 from the Veterans Health Administration Corporate Data Warehouse. Records were queried for clinical-demographic data, aspirin prescriptions, and outcomes. Three-year OS was estimated. A Cox model was used to estimate hazard ratios (HR) for aspirin use.

RESULTS: Among the 23 083 identified veterans, 17 206 veterans met inclusion criteria. 21.8% used aspirin. Three-year OS was prolonged for aspirin users (66%) compared to nonaspirin users (54%; P < .001). Adjusted HR for death for nonaspirin users was 1.75 (95% confidence interval (CI) [1.60-1.91]). The average treatment effect of aspirin on survival using inverse probability weighting was 10% (95% CI [0.08-0.11]).

English

Powered by Koha